BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

Treatment with botulinum toxin A appears to improve tear production and stability and relieve symptoms in patients with dry ...

Boehringer Ingelheim has raised hopes of a more patient-friendly option with the start of phase 2 testing of BI 1815368, ...

What’s powering a $26.28 billion opportunity?The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood ...

Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for neovascular AMD, diabetic macular edema, and other ocular conditions, ...

The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) with extended treatment intervals of up to 6 ...

Biocon Biologics, a subsidiary of Biocon Ltd, has received approval from Health Canada for Yesafili (aflibercept), a biosimilar to Eylea, marking the first such approval for an Eylea biosimilar in the ...

Biocon Biologics has received Health Canada's approval for Yesafili, a biosimilar injection for eye ailments. As the first Eylea biosimilar approved in Canada, Yesafili's launch is set for July 4, ...

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ...